Analysis of the domestic pharmaceutical market of anthelmintic medicines
Keywords:pharmaceutical market, market research, medicines, helminthiases
The problem of helminthiases is particularly relevant not only in veterinary medicine, but also in medical practice of mankind. Today, the spread of parasitic diseases concerns any country in the world, including countries with high living standards. The greatest danger is the fact that the vast majority of cases of the digestive system helminthiases is in children of the preschool and early school age. In all age groups of patients there is also a significant deterioration of the immune system and development of autoimmune diseases as a consequence of the disease.
Aim. To analyze the range of anthelmintic medicines presented at the pharmaceutical market of Ukraine.
Materials and methods. Distribution of anthelmintic medicines by their origin and dosage forms, as well as by price offers was studied at the level of the industrial area of Kharkiv and the Kharkiv region. The data processing was performed using the methods of economic and statistical analysis, and the results were processed using computer programs.
Results and discussion. The domestic market of anthelmintic medicines offers 19 medicines on the basis of praziquantel, mebendazole, albendazole, piperazine, pyrantel, levamisole and one medicine in the form of a herbal tea – tansy flowers. Medicines of the Ukrainian production are only 36.8 %, while the most (63.2 %) of medicinal products comes from manufacturers of the UK, France and India. Anthelmintic medicines are presented in 3 dosage forms, among them coated tablets dominate. The analysis of price offers on the example of those that are available in Kharkiv and the Kharkiv region, taking into account the offers of internet pharmacies, showed their significant variation (from 2 to 1248). Among the medicines with albendazole as the active ingredient the greatest difference of price offers is typical for vormil in the form of coated tablets.
Conclusions. It has been found that the existing range of anthelmintic medicines requires development and implementation of new domestic products in the industrial production. A particular attention should be paid to development of products based on the medicinal plant raw material.
Abbas, A. Diagnosis and recommended treatment of helminth infections / A. Abbas, W. Newsholme // Prescriber. – 2011. – Vol. 22, Issue 19. – Р. 56–64. doi : 10.1002/psb.814.
Clinical guidelines. Diagnosis and treatment manual / I. Broek, N. Harris, M. Henkens et al. – 2013 ed. – Médecins Sans Frontières, 2013. – P. 334.
Deepak, T. The Role of Helminths in Immunity / T. Deepak, K. Goyal // J. of Allergy and Therapy. – 2016. – Vol. 7, Issue 1. – P. 231–232. doi : 10.4172/2155–6121.1000231.
Van Riet, E. Chronic helminth infections induce immunomodulation: consequences and mechanisms / E. Van Riet, F. C. Hartgers, M. Yazdanbakhsh // Immunobiol. – 2007. – Vol. 212, Issue 6. – P. 475–490. doi : 10.1016/j.imbio.2007.03.009.
Tolochko, K. V. The basic approaches to pharmacotherapy of helminthiases and prospects of phytomedicines development for their treatment / K. V. Tolochko, L. I. Vishnevska // Clinical Pharmacy. – 2016. – Т. 20, Vol. 4. – P. 4–10.
Standard Treatment Guidelines / Ministry of Health. – 6–th ed. –GhanaNational Drugs Programme: GNDP, 2010. – P. 375–501.
Єршова, І. Б. Гельмінтози у дітей / І. Б. Єршова, Л. М. Осичнюк, Г. О. Мочалова // Перинатол. и педиатрия. – 2013. – № 2 (54). – С. 125–131.
Довідник лікарських засобів України [Електронний ресурс] : МОЗ України, Деп. фармац. діяльності. – К. : Iнфодиск, 2004.
Компендиум. Лекарственные препараты [Електронний ресурс]. – Режим доступу : http://compendium.com.ua/
Статистика : підруч. / С. С. Герасименко, А. В. Головач, А. М. Єріна та ін.; під наук. ред. С. С. Герасименка. – 2–е вид., перероб. і доп. – К. : КНЕУ, 2000. – 467 с.
Теорія статистики : навч. посібник / Г. І. Мостовий, А. О. Дігтяр, В. К. Гаркавий та ін. – Х. : Магістр, 2002. – 300 с.
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).